Cellectar Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cellectar Biosciences, Inc. on November 13, 2018. The report addresses a corporate governance event regarding the departure of a senior officer.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance metrics.
Material Changes
The material change reported is the resignation of John E. Friend II, M.D., from his positions as Vice President and Chief Medical Officer. His resignation is effective November 27, 2018.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items beyond the disclosed executive departure.
Key Facts for Investor Verification
- John E. Friend II, M.D. resigned as Vice President and Chief Medical Officer.
- The effective date of the resignation is November 27, 2018.
- The report was signed by Brian M. Posner, Chief Financial Officer, on November 16, 2018.
- Investors should verify if a replacement for the Chief Medical Officer has been appointed or if the role will be filled internally.